Several reports suggest that @entity136 ( @entity14113 ) plus S-1 combination ( @entity1412 ) is associated to prolong the survival in @entity1 with unresectable @entity788 ( @entity788 ). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of @entity1412 versus @entity14113 .Summary data from randomized trials and retrospective studies were searched in PubMed, EMBASE, Web of Science, and the Cochrane Library. Statistical analyses were conducted to calculate the hazard ratios (HRs) and relative risk (RR) with 95% confidence intervals (CIs) using random-effects models. Subgroup analyses based on the chemotherapy cycles were performed to explore the efficacy and @entity137 for therapy. Sensitivity analyses were conducted by removing specific studies to assess the effects of study quality.Between January 2004 and August 2012, 4 RCTs and 2 retrospective studies including a total of 1025 cases were identified. The @entity1349 ( @entity1349 ) (HR: 0.82; 95% CI, 0.70-0.96; P = 0.01) and progression-free survival (PFS) (HR: 0.65; 95% CI, 0.55-0.77; P < 0.001) for the @entity1412 arm were significantly longer than the @entity14113 arm. The differences in objective response rate (ORR) (RR: 1.24; 95% CI, 1.17-1.33; P < 0.001) and disease control rate (DCR) were also better in the @entity1412 arm (RR: 1.37; 95% CI, 1.19-1.59; P < 0.001). Grades 3 to 4 @entity137 in both the groups were similar except @entity1398 and @entity294 , which were more frequent in the @entity1412 arm (P < 0.001). In the subgroup analysis, the cycle for chemotherapy every 4 weeks has equivalent efficacy and less @entity137 than regimens every 3 weeks in the @entity1412 arm.The current meta-analysis suggested that @entity14113 significantly prolonged @entity1349 and PFS when added to S-1 combination in @entity1 with unresectable @entity788 . @entity1412 therapy also offers better ORR and DCR than @entity14113 monotherapy and no unexpected @entity137 was evident.

@entity136 Compared With XXXX and S-1 Combination Therapy in Advanced @entity788 : A Systematic Review and Meta-Analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['PC', 'pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity14113 :: ('C056507', 'Chemical') :: ['GEM'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['GS'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
